ClinicalTrials.gg
RecruitingNCT07198659NeuMed-uPCUpdated Sep 30, 2025

A Single-Arm Investigator-Initiated Tria (IIT) Evaluating the Safety and Preliminary Efficacy of Autologous Drug-Loaded Neutrophils (NeuMed) in Patients With Unresectable Pancreatic Cancer

An Early Phase 1 interventional study of Monomethyl Auristatin E (MMAE) / autologous neutrophil biological agents in Unresectable Pancreatic Cancer, sponsored by The First Affiliated Hospital of Air Force Medicial University. Recruiting at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-09-30.

Sponsored by The First Affiliated Hospital of Air Force Medicial University · Early Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
3
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 635 studies in Pancreatic Neoplasms with a site in China — 338 open to participants now, 363 under way, 30 of them phase 3. Pancreatic Neoplasms · China.

Planned enrollment
504th of 513
3 · median 57
Started
2025
with 84 others
Phase 1
111 of 635
61 open now
Primary completion
2027-07
later than 251 of 362 live
Registered
541st of 635
by date

Among the 635 studies in Pancreatic Neoplasms with a site in China, this one is the 504th largest by planned enrollment of the 513 interventional ones that give a count, is one of 85 that started in 2025, is one of 111 in phase 1, reaches primary completion later than 251 of the 362 other live ones, and was the 541st registered.

Pancreatic Neoplasms

3,904 studies on the registry are indexed under Pancreatic Neoplasms; 1,005 are open to participants now.

Browse Pancreatic Neoplasms studies →

Open to participants now

338 of the 635 studies in Pancreatic Neoplasms with a site in China are open now. Recruiting first, the newest first:

333 more — sign in →

All 338 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 743 Pancreatic Neoplasms studies recruiting now, 476 (64%) set no upper age limit and 153 (21%) stop at 75 or younger; 40 take children under 18; 60 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 635 studies in Pancreatic Neoplasms with a site in China, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if Autologous Drug-Loaded Neutrophils (NeuMed) can treat patients with Unresectable Pancreatic Cancer. The drug carried by the Autologous Neutrophils is Monomethyl Auristatin E. The main questions it aims to answer are: First, to verify the safety of Autologous Drug-Loaded Neutrophils (NeuMed) in patients with Unresectable Pancreatic Cancer. Second, to assess the anti-tumor efficacy of Autologous Drug-Loaded Neutrophils (NeuMed) in patients with Unresectable Pancreatic Cancer.

Read the detailed description

In this open, single-armed study, selected patients with Unresectable Pancreatic Cancer confirmed by Histopathology will be received Autologous Drug-Loaded Neutrophils (NeuMed)-based therapy. Neutrophils will be isolated using a blood cell separator and cultured in a GMP-compliant laboratory to prepare neutrophil biological agents, which will then be loaded with the anti-tumor peptide, Monomethyl Auristatin E (MMAE).

03

Conditions studied

  • Unresectable Pancreatic Cancer

Keywords

  • Autologous Drug-Loaded Neutrophils (NeuMed)
  • Unresectable Pancreatic Cancer
  • Monomethyl Auristatin E (MMAE)
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18-70 years
  • Obtain an form voluntarily signed by the patient themselves
  • patients with Unresectable Pancreatic Cancer confirmed by Histopathology
  • Patients who either: 1) have received standard treatments, proven ineffective or causing intolerable adverse effects; or 2) have not received the standard first-line treatments and voluntarily opt for Autologous Drug-Loaded Neutrophils (NeuMed)-based therapy
  • EOCG score ≤ 2 and expected survival time ≥ 3 months
  • Liver, kidney and bone marrow functions are basically normal

Exclusion criteria

Exclusion Criteria:

  • Patients who required anti coagulant therapy
  • Patients with active infectious diseases or a history of bone marrow or organ transplantation
  • Patients with diseases or autoinflammatory diseases
  • Patients with a history of severe cardiovascular or cerebrovascular diseases or interstitial lung disease or non-infectious pneumonia
  • Patients who have received within 30 days prior to enrollment
  • Patients with no response to bone marrow mobilization
  • Other patients deemed unsuitable for enrollment by the investigator
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
3 participants (estimated)

Study arms

  • Experimental
    Monomethyl Auristatin E (MMAE) / autologous neutrophil biological agents

    Isolate the patients' autologous neutriphil cells, induce and culture them with Monomethyl Auristatin E (MMAE) in a GMP-compliant laboratory. Prior to the reinfusion of neutrophil biological agents into patients, stereotactic radiotherapy with a dose of 2-6 Gy is administered to pancreatic cancer lesions. The number of neutrophils that were reinfused was 2.0-8.0x10\^8.

    Combination Product: Monomethyl Auristatin E (MMAE) / autologous neutrophil biological agents

Interventions

  • Combination productMonomethyl Auristatin E (MMAE) / autologous neutrophil biological agents

    Isolate the patients' autologous neutriphil cells, induce and culture them with Monomethyl Auristatin E (MMAE) in a GMP-compliant laboratory. Prior to the reinfusion of neutrophil biological agents into patients, stereotactic radiotherapy with a dose of 2-6 Gy is administered to pancreatic cancer lesions. The number of neutrophils that were reinfused was 2.0-8.0x10\^8.

06

What researchers measure

Primary outcomes

  1. To verify the safety of Autologous Drug-Loaded Neutrophils (NeuMed) in patients with Unresectable Pancreatic Cancer

    Incidence rate of Adverse Events(For the grading of treatment-related adverse events, all cases were classified with reference to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE)). Developed by the National Cancer Institute (NCI), the Common Terminology Criteria for Adverse Events (CTCAE) is currently the most widely used adverse event (AE) grading system, applicable to oncology clinical trials. It classifies adverse events into 5 grades:Grade 1 (Mild): Asymptomatic or mild in severity, with no requirement for intervention;Grade 2 (Moderate): Requiring medical intervention and causing mild impairment of daily activities;Grade 3 (Severe): Resulting in significant functional impairment, necessitating hospitalization or substantial medical intervention, and rendering the patient unable to perform daily activities;Grade 4 (Life-threatening): Pose a threat to life and require urgent intervention;Grade 5 (Death): Directly caused by the adverse event.

    Time frame: 12 months

Secondary outcomes

  1. To assess the anti-tumor efficacy of Autologous Drug-Loaded Neutrophils (NeuMed) in patients with Unresectable Pancreatic Cancer

    Objective Response Rate (ORR);The ORR is determined by measuring the size of target and non-target tumor lesions in follow-up imaging data, in accordance with the Response Evaluation Criteria in Solid Tumors (RECIST). The Response Evaluation Criteria in Solid Tumors (RECIST) classifies tumor response to treatment into distinct categories based on changes in the size of target lesions (and non-target lesions, as applicable) and the presence of new lesions, with the following specific grading framework:Complete Response (CR);Partial Response (PR);Stable Disease (SD);Progressive Disease (PD). Imaging modalities for lesion measurement (e.g., contrast-enhanced CT, MRI) must be consistent throughout follow-up to ensure the reliability of SLD calculations, as mandated by the specific grading criteria in RECIST.

    Time frame: 12 months

07

Study locations

1 of 1 sites recruiting
  • The First Affiliated Hospital of the PLA Air Force Military Medical University
    Xi’an, Shanxi 710000, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Jul 2027, 24 months after the start.

Of 209 non-industry phase 1 interventional studies under Pancreatic Neoplasms, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 74. This study's planned 24 months is below that.

Counting every sponsor, half of 380 studies reached it within 45 months; a quarter within 32 and three quarters within 68.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 15, 2025
First posted
Sep 30, 2025
StartActual
Jul 14, 2025
Primary completionEst.
Jul 14, 2027
CompletionEst.
Jul 14, 2027
Last update
Sep 30, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 30, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07198659
Lead sponsor
The First Affiliated Hospital of Air Force Medicial University
Responsible party
Lin Wang (Professor, The First Affiliated Hospital of Air Force Medicial University) — Principal investigator
First posted
Sep 30, 2025
Start date
Jul 14, 2025
Primary completion
Jul 14, 2027 (estimated)
Completion
Jul 14, 2027 (estimated)
Last update
Sep 30, 2025

Study contacts

Liang Jin, Doctor of Medicine(M.D.)
Contact
jinl2013@163.com
02984775260 ext. 18392388395
Lin Wang, Doctor of Medicine(M.D.)
Contact
02984775260 ext. 13709113260
Lin Wang, Doctor of Medicine(M.D.)
study director · The First Affiliated Hospital of Air Force Military Medical University
Liang Jin, Doctor of Medicine(M.D.)
principal investigator · The First Affiliated Hospital of Air Force Military Medical University
Yong Chen, Doctor of Medicine(M.D.)
principal investigator · The First Affiliated Hospital of Air Force Military Medical University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion